XERS
Xeris Stock Jumps 25% as Quarterly Revenue Rises 44% and Full-Year Guidance Is Raised
The company also raised its 2030 revenue outlook to more than $1 billion and said Recorlev is on a faster path to nearly $1 billion in annual net revenue.
Xeris Biopharma XERS
Xeris Biopharma Holdings, Inc. · Nasdaq · Pharmaceutical Preparations
$13.08+25.05%close on Nov. 5, 2026 · volume 12.3M · Yahoo Finance
Price, last 53 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Nov. 2, 2026 | Steven Pieper See Remarks | Sold 10b5-1 plan | 5,000 | $10.23 | $51,174 |
| Nov. 2, 2026 | Beth Hecht See Remarks | Sold 10b5-1 plan | 25,000 | $10.23 | $255,828 |
| Nov. 2, 2026 | Kevin McCulloch See Remarks | Sold 10b5-1 plan | 15,000 | $10.23 | $153,488 |
| Oct. 1, 2026 | Steven Pieper See Remarks | Sold 10b5-1 plan | 5,000 | $9.41 | $47,036 |
| Oct. 1, 2026 | Kevin McCulloch See Remarks | Sold 10b5-1 plan | 15,000 | $9.41 | $141,120 |
| Oct. 1, 2026 | Beth Hecht See Remarks | Sold 10b5-1 plan | 16,666 | $9.41 | $156,792 |
| Sept. 28, 2026 | Kevin McCulloch See Remarks | Sold 10b5-1 plan | 25,000 | $10.00 | $250,000 |
| Sept. 1, 2026 | Kevin McCulloch See Remarks | Sold 10b5-1 plan | 15,000 | $8.49 | $127,308 |
| Sept. 1, 2026 | Beth Hecht See Remarks | Sold 10b5-1 plan | 16,666 | $8.49 | $141,434 |
| Sept. 1, 2026 | Steven Pieper See Remarks | Sold 10b5-1 plan | 5,000 | $8.50 | $42,500 |
| Aug. 12, 2026 | Steven Pieper See Remarks | Sold 10b5-1 plan | 5,000 | $8.50 | $42,500 |
| Aug. 3, 2026 | Kevin McCulloch See Remarks | Sold 10b5-1 plan | 15,000 | $8.02 | $120,240 |
Latest 12 of 13. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 25 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedXeris Biopharma Q3 2026 diluted EPS $0.06 beats $0.027 consensus; revenue $107.2 million tops $101.7 million; full-year revenue guidance raised to $395-$405 million
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedXeris Biopharma Appoints Menassie Taddese to Board of Directors and Audit Committee